Working… Menu
Trial record 1 of 1 for:    NCT02936323
Previous Study | Return to List | Next Study

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02936323
Recruitment Status : Completed
First Posted : October 18, 2016
Last Update Posted : March 11, 2021
Information provided by (Responsible Party):
Tarveda Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 31, 2020
Actual Study Completion Date : February 25, 2021